Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/147966
Title: | MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways |
Author: | Majem, Blanca Parrilla, Alfonso Jiménez, Carlos Marin, Andrea Suárez, Leticia Castellví, Josep Tamayo, Gabriel Moreno, Gema Ponce i Sebastià, Jordi Matias-Guiu, Xavier Alameda, Francesc Romero, Ignacio Sánchez, José Luis Pérez Benavente, Asunción Moran, Sebastian Esteller, Manel Reventós Puigjaner, Jaume Rigau, Marina Gil Moreno, Antonio Segura, Miguel F. Santamaría Margalef, Anna |
Keywords: | Apoptosi Epigenètica Micro RNAs Càncer d'ovari Apoptosis Epigenetics MicroRNAs Ovarian cancer |
Issue Date: | 5-Jul-2019 |
Publisher: | National Academy of Sciences |
Abstract: | Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41388-019-0860-0 |
It is part of: | Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 38, p. 6035-6050 |
URI: | https://hdl.handle.net/2445/147966 |
Related resource: | https://doi.org/10.1038/s41388-019-0860-0 |
ISSN: | 0027-8424 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
682225.pdf | 5.46 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.